May 17, 2016 : DCMS #293

DISASTERS AVERTED — Near Miss Case Studies

It IS What You Say

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Eran Bashan Part 4,  Patient Support

HOMERUN SLIDES — Great Clinical Presentation Highlights

Diagnosing Diabetes Mellitus in Adults Part 4

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #24: Pancreatic Morphology in Normal and Diabetic States, Part 4 of 4

MOST POPULAR ARTICLES OF THE MONTH

#1 What is the Actual Cost of Insulin for Your Patients?
#2 Make the Goal Personal to Motivate
#3 Quality of Life Versus Shorter Lives with Diabetes

For many years we have known that amyloid deposits in the brain cause Alzheimer’s, and the more deposits the worse the disease becomes. In 2011 scientists from ModGene LLC and Scripps Research Institute found that these deposits in the brain may come from the liver. This week our clinical text looks at how these amyloid deposits also develop on the beta cells of the pancreas.

Your partner in diabetes care,
Dave Joffe
Editor-in-chief

Working with a patient, a woman, 44 years of age, who has had type 1 diabetes 21 years. She had a day of high glucose levels. We worked together very hard all day correcting to bring it down. After being closer to her target range, not low by any means, she told me she just had some chocolate. I asked her why, after the day she had, did she choose chocolate.

In part 4 of this Exclusive Interview, Eran Bashan explains how diabetes educators and physicians provide patient support with the d-Nav solution.

In this week’s Homerun Slides, we continue exploring the mechanisms of diabetes with a brief focus on immune modulation/inflammation, insulin resistance and environment.

Chronically elevated glucose and/or free fatty acids: type 2 diabetes is characterized by increased circulating nutrients including glucose and free fatty acids (FFA).The literature clearly shows that chronic exposure of beta cells to elevated glucose results in impaired beta-cell function, but the data regarding cellular toxicity in response to this nutrient are more mixed.

For patients in the U.S., the price of this lifesaving treatment has risen dramatically.

Male, 66 years of age, type 2 diabetes, class III obesity, peripheral neuropathy, multiple toe amputations, hypertension, hyperlipidemia and, most importantly, a 2-year-old granddaughter. Patient taking 100 units long-acting insulin, sulfonylurea, metformin, beta blocker, and statin. Checks glucose once in a while; in the 200 to 270 range when checks. A1C 9.3%.

According to a new study, people with diabetes have a slightly shorter life expectancy than people without diabetes, and many of those years will be marred by disability.